AU2018215673B2 - Compositions and methods for augmenting antibody mediated receptor signaling - Google Patents

Compositions and methods for augmenting antibody mediated receptor signaling Download PDF

Info

Publication number
AU2018215673B2
AU2018215673B2 AU2018215673A AU2018215673A AU2018215673B2 AU 2018215673 B2 AU2018215673 B2 AU 2018215673B2 AU 2018215673 A AU2018215673 A AU 2018215673A AU 2018215673 A AU2018215673 A AU 2018215673A AU 2018215673 B2 AU2018215673 B2 AU 2018215673B2
Authority
AU
Australia
Prior art keywords
antibody
amino acid
polypeptide
region
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018215673A
Other languages
English (en)
Other versions
AU2018215673A1 (en
Inventor
Wayne A. Marasco
Quan Karen ZHU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of AU2018215673A1 publication Critical patent/AU2018215673A1/en
Application granted granted Critical
Publication of AU2018215673B2 publication Critical patent/AU2018215673B2/en
Priority to AU2025202811A priority Critical patent/AU2025202811A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2018215673A 2017-02-06 2018-02-06 Compositions and methods for augmenting antibody mediated receptor signaling Active AU2018215673B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025202811A AU2025202811A1 (en) 2017-02-06 2025-04-22 Compositions and methods for augmenting antibody mediated receptor signaling

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762455245P 2017-02-06 2017-02-06
US62/455,245 2017-02-06
PCT/US2018/017027 WO2018145075A1 (en) 2017-02-06 2018-02-06 Compositions and methods for augmenting antibody mediated receptor signaling

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025202811A Division AU2025202811A1 (en) 2017-02-06 2025-04-22 Compositions and methods for augmenting antibody mediated receptor signaling

Publications (2)

Publication Number Publication Date
AU2018215673A1 AU2018215673A1 (en) 2019-07-25
AU2018215673B2 true AU2018215673B2 (en) 2025-01-23

Family

ID=63040120

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018215673A Active AU2018215673B2 (en) 2017-02-06 2018-02-06 Compositions and methods for augmenting antibody mediated receptor signaling
AU2025202811A Pending AU2025202811A1 (en) 2017-02-06 2025-04-22 Compositions and methods for augmenting antibody mediated receptor signaling

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025202811A Pending AU2025202811A1 (en) 2017-02-06 2025-04-22 Compositions and methods for augmenting antibody mediated receptor signaling

Country Status (7)

Country Link
US (2) US20220213206A1 (enExample)
EP (1) EP3576793A4 (enExample)
JP (3) JP7231549B2 (enExample)
CN (1) CN110520158A (enExample)
AU (2) AU2018215673B2 (enExample)
CA (1) CA3049689A1 (enExample)
WO (1) WO2018145075A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019001262A2 (pt) * 2016-07-22 2019-05-07 Dana-Farber Cancer Institute, Inc. anticorpos para o receptor do fator de necrose de tumor induzido por glicocorticoide (gitr) e métodos de uso dos mesmos
MD3823665T2 (ro) 2018-07-19 2024-05-31 Regeneron Pharma Receptori antigenci chimerici cu specificitate BCMA și utilizările acestora
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
RU2734432C1 (ru) 2019-04-23 2020-10-16 Закрытое Акционерное Общество "Биокад" Моноклональное антитело, которое специфически связывается с GITR
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
CA3173944A1 (en) 2021-01-13 2022-07-21 Visterra, Inc. Humanized complement 5a receptor 1 antibodies and methods of use thereof
US20240239905A1 (en) * 2021-05-13 2024-07-18 Arizona Board Of Regents On Behalf Of Arizona State University A plant produced anti-egfr mabs with specific glycosylation to improve the efficacy against cancer
CN115873126A (zh) * 2021-11-26 2023-03-31 深圳科兴药业有限公司 人生长激素融合蛋白及其制备和用途
AU2023324669A1 (en) 2022-08-15 2025-02-13 Dana-Farber Cancer Institute, Inc. Antibodies against msln and methods of use thereof
EP4572785A1 (en) 2022-08-15 2025-06-25 Dana-Farber Cancer Institute, Inc. Antibodies against cldn4 and methods of use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150353636A1 (en) * 2013-01-10 2015-12-10 Genmab B.V. Human igg1 fc region variants and uses thereof
WO2016139365A1 (en) * 2015-03-05 2016-09-09 Ucb Biopharma Sprl Polymeric fc proteins and methods of screening to alter their functional characteristics
WO2016164480A1 (en) * 2015-04-07 2016-10-13 Genentech, Inc. Antigen binding complex having agonistic activity and methods of use
WO2018083126A1 (en) * 2016-11-01 2018-05-11 Genmab B.V. Polypeptide variants and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5912224A (en) * 1996-02-22 1999-06-15 The General Hospital Corporation Methods and compositions for enhancing cellular response to TGF-β ligands
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization
AU2015200990B2 (en) * 2009-03-20 2016-07-21 Laboratoire Français Du Fractionnement Et Des Biotechnologies Optimized Fc variants
CN104736174B (zh) * 2012-07-06 2019-06-14 根马布私人有限公司 具有三重突变的二聚体蛋白质
WO2014122143A1 (en) * 2013-02-05 2014-08-14 Engmab Ag Method for the selection of antibodies against bcma
MA40609B1 (fr) * 2014-09-05 2020-05-29 Janssen Pharmaceutica Nv Agents de liaison cd123 et leurs utilisations
DK3215528T3 (da) * 2014-11-06 2019-10-07 Hoffmann La Roche Fc-regionvarianter med modificeret FcRn-binding og anvendelsesfremgangsmåder
CN120795163A (zh) * 2016-10-14 2025-10-17 丹娜法伯癌症研究所公司 模块化四聚体双特异性抗体平台

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150353636A1 (en) * 2013-01-10 2015-12-10 Genmab B.V. Human igg1 fc region variants and uses thereof
WO2016139365A1 (en) * 2015-03-05 2016-09-09 Ucb Biopharma Sprl Polymeric fc proteins and methods of screening to alter their functional characteristics
WO2016164480A1 (en) * 2015-04-07 2016-10-13 Genentech, Inc. Antigen binding complex having agonistic activity and methods of use
WO2018083126A1 (en) * 2016-11-01 2018-05-11 Genmab B.V. Polypeptide variants and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DI ZHANG ET AL: "Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 291, no. 53, 30 December 2016 (2016-12-30), pages 27134 - 27146 *

Also Published As

Publication number Publication date
AU2018215673A1 (en) 2019-07-25
CA3049689A1 (en) 2018-08-09
WO2018145075A1 (en) 2018-08-09
JP7606501B2 (ja) 2024-12-25
EP3576793A1 (en) 2019-12-11
CN110520158A (zh) 2019-11-29
US20220213206A1 (en) 2022-07-07
US20240336694A1 (en) 2024-10-10
JP7231549B2 (ja) 2023-03-01
JP2023036899A (ja) 2023-03-14
AU2025202811A9 (en) 2026-03-05
JP2025028191A (ja) 2025-02-28
AU2025202811A1 (en) 2025-05-08
EP3576793A4 (en) 2021-03-31
JP2020505054A (ja) 2020-02-20

Similar Documents

Publication Publication Date Title
US20240336694A1 (en) Compositions and methods for augmenting antibody mediated receptor signaling
CN113286821B (zh) 靶向肿瘤的激动性cd28抗原结合分子
US20250066481A1 (en) Fc variant compositions and methods of use thereof
JP7397882B2 (ja) 二重特異性抗体及びその調製方法、使用
JP7596263B2 (ja) ４－１ｂｂ及び腫瘍関連抗原に結合する抗体構築物ならびにその使用
CA3119968A1 (en) Antibodies to mucin-16 and methods of use thereof
US20230265202A1 (en) Antibody constructs binding 4-1bb and folate receptor alpha and uses thereof
RU2819624C2 (ru) Композиции анти-cd112r антител и сопутствующие способы
US20240132593A1 (en) Anti-vista antibodies and uses thereof
CN120322455A (zh) 特异性识别b和t淋巴细胞衰减器(btla)的抗体及其应用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)